Lilly and Resilience invest $750M in diabetes and obesity drug device supply
The $750M investment will expand Resilience's US capacity to make the KwikPen device Eli Lilly uses to deliver its injectable diabetes and obesity medicines.
Resilience (National Resilience)
Private
Biomanufacturing CDMO improving access to complex medicines through end-to-end biologics manufacturing, cell therapy and drug product fill-finish; investing $750M with Eli Lilly to expand US KwikPen device capacity.
Company Info
Sector:CDMO / Biomanufacturing
Headquarters:San Diego, California, USA
Founded:2020
Website:resilience.com/
Upcoming Milestones & Key Dates
2026 H2
Corporate
Lilly/Resilience $750M Cincinnati expansion for KwikPen device
Recent News
Leadership Team
Rahul Singh
Founder and Chief Executive Officer
Careers & Job Openings